Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18856407 | 0.84 | MAOB (0.38) | HTTLMNASMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL1772519 | 0.82 | BIRC5 (0.47) | BIRC5KMT2AMEN1PDE10A | |
| SCHEMBL6933468 | 0.81 | PDGFRB (0.53) | SMN1; SMN2CALM1KMT2AMEN1ALDH1A1 | |
| SCHEMBL22926854 | 0.81 | PDE10A (0.49) | HTTSMN1; SMN2CALM1KMT2AMEN1 | |
| SCHEMBL2621781 | 0.78 | BACE1 (0.38) | HTTLMNASMN1; SMN2BIRC5KMT2A | |
| SCHEMBL18562139 | 0.78 | CYP1A2 (0.40) | HTTLMNASMN1; SMN2BIRC5CCNC | |
| SCHEMBL25258837 | 0.77 | PDGFRB (0.60) | KMT2AMEN1PTGESGABRG2GABRB3 | |
| SCHEMBL31052337 | 0.77 | PDGFRB (0.60) | KMT2AMEN1PTGESGABRG2GABRB3 | |
| SCHEMBL9638 | 0.75 | TLR2 (0.37) | HTTBIRC5KMT2AMEN1CYP2A6 | |
| SCHEMBL12850737 | 0.75 | MALT1 (0.38) | HTTBIRC5KMT2AMEN1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912647-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERICAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-11 | — | — | EP | disclosed |
| EP-2301544-B1 | Quinoline derivatives as intermediates to mycobacterial inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-19 | — | — | EP | disclosed |
| US-8017606-B2 | Therapy for bacteria infections other than Mycibacterium infections; antibiotic resistance | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-13 | — | — | US | disclosed |
| US-8017606-B2 | Therapy for bacteria infections other than Mycibacterium infections; antibiotic resistance | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-13 | — | — | US | disclosed |
| US-20110124870-A1 | NOVEL MYCOBACTERIAL INHIBITORS | JANSSEN-CILAG (FR) | 2011-05-26 | — | — | US | disclosed |
| US-20110124870-A1 | NOVEL MYCOBACTERIAL INHIBITORS | JANSSEN-CILAG (FR) | 2011-05-26 | — | — | US | disclosed |
| EP-2301544-A1 | Quinoline derivatives as intermediates to mycobacterial inhibitors | Janssen Pharmaceutica N.V. (BE) | 2011-03-30 | — | — | EP | disclosed |
| US-7902225-B2 | Mycobacterial inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | disclosed |
| US-7902225-B2 | Mycobacterial inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | disclosed |
| US-7498343-B2 | Quinolines; 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-ol; Mycobacterium tuberculosis, M. bovis, M. avium and M. marinum; reduces the total length of treatment and the frequency of drug administration; multi-drug and antibiotic resistance | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-03 | — | — | US | disclosed |
| US-7498343-B2 | Quinolines; 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-ol; Mycobacterium tuberculosis, M. bovis, M. avium and M. marinum; reduces the total length of treatment and the frequency of drug administration; multi-drug and antibiotic resistance | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-03 | — | — | US | disclosed |
| US-20080255116-A1 | Therapy for bacteria infections other than Mycibacterium infections; antibiotic resistance | JANSSEN PHARMACEUTICA N.V. | 2008-10-16 | — | — | US | disclosed |
| US-20080255116-A1 | Therapy for bacteria infections other than Mycibacterium infections; antibiotic resistance | JANSSEN PHARMACEUTICA N.V. | 2008-10-16 | — | — | US | disclosed |
| US-20070093478-A1 | Novel mycobacterial inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093478-A1 | Novel mycobacterial inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124870-A1 | NOVEL MYCOBACTERIAL INHIBITORS | NQO2, NAT1, HRH1 | HTT 463/4885LMNA 2927/4885SMN1; SMN2 4270/4885 |
| US-20070093478-A1 | Novel mycobacterial inhibitors | NQO2, NAT1, HRH1 | HTT 534/4885LMNA 2887/4885SMN1; SMN2 4301/4885 |
| US-20080255116-A1 | Therapy for bacteria infections other than Mycibacterium infections; antibiotic resistance | RER1, HRH4, HRH1 | HTT 898/4885LMNA 4062/4885SMN1; SMN2 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.